uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
Rhea-AI Summary
uniQure (NASDAQ: QURE) received final FDA minutes from a Jan 30, 2026 Type A meeting about AMT-130 for Huntington’s disease. The FDA said Phase I/II data versus an external control are not sufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.
uniQure plans further engagement and intends to request a Type B meeting in Q2 2026 to discuss Phase III design options.
Positive
- FDA provided clear, specific trial-design guidance for AMT-130
- uniQure plans a Type B meeting in Q2 2026 to discuss Phase III
Negative
- FDA concluded Phase I/II data versus external control are insufficient for approval
- Regulator strongly recommended a randomized, double-blind, sham-controlled Phase III trial
News Market Reaction – QURE
On the day this news was published, QURE declined 32.82%, reflecting a significant negative market reaction. Argus tracked a trough of -54.2% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $476M from the company's valuation, bringing the market cap to $974M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
QURE’s -8.68% move contrasts with mixed peer action: EYPT, ABUS, OCS, and UPB show modest declines while TSHA is slightly positive. No peers appeared in the momentum scanner, suggesting today’s move is stock-specific rather than a broad gene therapy or biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Earnings date announcement | Neutral | +4.4% | Set timing for Q4 and full-year 2025 results and conference call. |
| Feb 06 | Clinical data update | Positive | +4.6% | Reported sustained, dose-dependent α-Gal A increases in 11 Fabry patients. |
| Jan 09 | Regulatory meeting news | Positive | +9.4% | Announced Type A FDA meeting on AMT-130 BLA package and accelerated approval path. |
| Dec 07 | Durability publication | Positive | +2.1% | Published 5-year HEMGENIX durability and safety data in NEJM with strong outcomes. |
| Dec 04 | Regulatory setback | Negative | -10.8% | FDA said AMT-130 Phase I/II data unlikely to provide primary BLA evidence. |
Recent QURE news has generally seen price reactions aligned with news tone, including a sharp selloff on prior negative AMT-130 FDA feedback and gains on clinical and ownership updates.
Over the last few months, QURE has issued multiple updates spanning earnings timing, clinical data, and regulatory interactions. A Dec 4, 2025 FDA update on AMT-130, indicating Phase I/II data were unlikely to support a BLA, coincided with a -10.75% move. Positive Fabry disease AMT-191 data on Feb 6, 2026 and a Type A meeting announcement for AMT-130 on Jan 9, 2026 both saw mid-single to high-single-digit gains, showing sensitivity to clinical and regulatory signals.
Market Pulse Summary
The stock dropped -32.8% in the session following this news. A negative reaction despite ongoing dialogue fits QURE’s history of sharp moves around AMT-130 regulatory updates, including the -10.75% drop on Dec 4, 2025 after earlier FDA feedback. The FDA’s view that Phase I/II data are insufficient for a marketing application, and its push for a randomized, sham-controlled study, adds development and timing risk. Past sensitivity to regulatory news suggests that setbacks in this program have previously translated into meaningful share-price pressure.
Key Terms
type a meeting regulatory
type b meeting regulatory
phase i/ii medical
phase iii medical
double-blind medical
sham surgery-controlled medical
gene therapy medical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).
The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for AMT-130. The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study. uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.
“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said Matt Kapusta, chief executive officer at uniQure. “We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130. We are deeply grateful for the resilience and support of the Huntington’s disease community and remain committed to standing with patients and their families as we advance this potentially transformative therapy for a community in need.”
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions and the negatives of those terms. Forward-looking statements are based on management's beliefs and assumptions and on information available to management as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: plans to continue engaging with the FDA regarding Phase III development considerations for AMT-130; plans to request a Type B meeting with the FDA to take place in the second quarter of 2026; and the potential benefit of AMT-130. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/ll clinical trials of AMT-130, including the risk that such trials will be unable to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that more patient data become available that results in a different interpretation then the one derived from the topline data; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; the risk that we will be unable to align with the FDA or other regulatory authorities on an approval pathway for our gene therapy candidates, including AMT-130; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund a Phase III or confirmatory study for AMT-130; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (SEC), including its Annual Reports on Form 10-K , its Quarterly Reports on Form 10-Q and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
uniQure Contacts:
| FOR INVESTORS: Chiara Russo Direct: 781-491-4371 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
FAQ
What did the FDA tell uniQure about AMT-130 on January 30, 2026 (QURE)?
Will uniQure (QURE) advance AMT-130 to a Phase III randomized sham-controlled study?
What does the FDA recommendation mean for AMT-130 approval timeline for uniQure (QURE)?
How will uniQure (QURE) engage the FDA after the Type A meeting on AMT-130?
Did the FDA agree that uniQure’s Phase I/II AMT-130 data are sufficient for a marketing application (QURE)?
What is uniQure’s public response after the FDA feedback on AMT-130 (QURE)?
